Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - alprostadil 10 µg/0,5 ml - poudre et solvant pour solution injectable - 10 µg - alprostadil 12.8 µg - alprostadil

Union européenne - français - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - néoplasmes prostatiques - la thérapie endocrinienne - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - néoplasmes prostatiques - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

wala schweiz gmbh - viscum album d3 10,0 mg / 1 gramm; granit, d9, 10.0 mg / 1 gramm; brennnessel-smarts, d2, 10.0 mg / 1 gramm; prostata, d5, 10.0 mg / 1 gramm; berberis gemeinsamen, tm, 3,4 mg / 1 gramm; magnesium sulfuricum d5, 10.0 mg / 1 gramm; oxalis acetosella, d2, 10.0 mg / 1 gramm; berberis gemeinsamen, tm, 6,6 mg / 1 gramm - b - granit, d9, 10.0 mg / 1 gramm; viscum album, d3, 10.0 mg / 1 gramm; prostata, d5, 10.0 mg / 1 gramm; urtica urens, d2, 10.0 mg / 1 gramm; berberis vulgaris, tm, 3.4 mg / 1 gramm; magnesium sulfuricum, d5, 10.0 mg / 1 gramm; oxalis acetosella, d2, 10.0 mg / 1 gramm; berberis vulgaris, tm, 6.6 mg / 1 gramm - anthroposophisch

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

wala schweiz ag - berberis commun de la plante récente ferm d1, berberis commun e de la racine ferm d1, granit d9, magnésium sulfamidés heptahydricus d5, oxalis acetosella e usine de l'ensemble de la ferm d2, prostata vache gl d5, l'ortie, la combustion de l'herbe fraîche et ferm d2, viscum album (abietis) e usine de l'ensemble de la ferm d3 - solutio ad injectionem - berberis commun de la plante récente ferm d1 0.067 g, berberis commun e de la racine ferm d1 de 0,033 g, granit d9 0,1 g, magnésium sulfamidés heptahydricus d5 0,1 g, oxalis acetosella e usine de l'ensemble de la ferm d2 0,1 g, prostata vache gl d5 0,1 g, l'ortie, la combustion de l'herbe fraîche et ferm d2 0,1 g, viscum album (abietis) e usine de l'ensemble de la ferm d3 0,1 g, natrii chloridum, natrii hydrogenocarbonas, de l'eau ad iniectabilia, à la solution de 1 ml. - sans indication, - médicaments anthroposophiques

Canada - français - Health Canada

pfizer canada ulc - alprostadil - solution - 500mcg - alprostadil 500mcg - miscellaneous vasodilatating agents

Canada - français - Health Canada

pfizer canada ulc - alprostadil - trousse - 20mcg - alprostadil 20mcg - miscellaneous vasodilatating agents

Canada - français - Health Canada

pfizer canada ulc - alprostadil - poudre pour solution - 20mcg - alprostadil 20mcg - miscellaneous vasodilatating agents

Canada - français - Health Canada

pfizer canada ulc - alprostadil - poudre pour solution - 11.9mcg - alprostadil 11.9mcg - miscellaneous vasodilatating agents

Canada - français - Health Canada

pfizer canada ulc - alprostadil; eau - trousse - 11.9mcg; 99.1% - alprostadil 11.9mcg; eau 99.1% - miscellaneous vasodilatating agents